Tasly subsidiary gets clinical trial nod for new cancer drug

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Tasly Pharmaceutical Group Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of TSL2109 capsules for advanced solid tumors. This approval, granted on July 23, 2025, allows the company to proceed with clinical development for the Class 1 chemical drug.

TSL2109 capsules are a newly structured dual-target small molecule inhibitor, jointly developed by Jiangsu Tasly Diyi and China Pharmaceutical University. The drug is designed to inhibit downstream signaling pathways of dual targets, block tumor cell cycles, and induce tumor cell apoptosis, leading to synergistic tumor cell killing. Each capsule will be available in 100 mg and 25 mg dosages.

As of the announcement date, Jiangsu Tasly Diyi has invested a cumulative RMB 24,625,100 in the research and development of TSL2109 capsules. The company highlighted that there are currently no similar dual-target drugs in clinical trial phases globally.